Ovarian Cancer | Specialty

Biomarker-Driven Frontline Ovarian Cancer Treatment

July 20th 2020

An Introduction to the Discussion of Ovarian Cancer

July 20th 2020

Dr. Moore on Unmet Clinical Needs in Platinum-Resistant Ovarian Cancer

July 17th 2020

Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.

Dr. Gilbert on the Safety Profile of Mirvetuximab Soravtansine/Bevacizumab in Ovarian Cancer

July 16th 2020

Lucy Gilbert, MD, MSc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Public Mistrust May Undermine HPV and COVID-19 Vaccines

July 14th 2020

These are disquieting times for clear and decisive messaging regarding vaccines.

Olaparib Plus Bevacizumab Combination Expands Options in HRD+ Cancer

July 4th 2020

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

Dr. Matulonis on the Current Treatment Landscape in Ovarian Cancer

July 2nd 2020

Ursula A. Matulonis, MD, discusses the current treatment landscape in ovarian cancer.

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

June 25th 2020

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

June 24th 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Novel ADC STRO-002 Shows Early Promise in Heavily Pretreated Epithelial Ovarian Cancer

June 23rd 2020

R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.

Lipophilic Statin Use Is Associated With Decreased Mortality in Epithelial Ovarian Cancer

June 22nd 2020

Findings from an observational study of more than 10,000 women with ovarian cancer showed that lipophilic statins were associated with a 43% overall reduction in epithelial ovarian cancer mortality, with declines seen across subtypes.

Niraparib’s Indication Expands in Ovarian Cancer

June 19th 2020

Bhavana Pothuri, MD, discusses the practice-changing implications of niraparib’s approval in ovarian cancer.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 11th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Dr. Swisher on the Phase III VELIA Results in Ovarian Cancer

June 7th 2020

Elizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

June 3rd 2020

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

June 2nd 2020

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Updated AVANOVA2 Survival Data Further Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer

May 30th 2020

Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.

Mirvetuximab Soravtansine Combination Shows Positive Response, Tolerability in Ovarian Cancer

May 30th 2020

Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status with a favorable tolerability profile.

Cediranib/Olaparib Combo Yields Comparable Results to Chemo in Ovarian Cancer Treatment

May 29th 2020

A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.